Cas:59785-64-7 1-propanoylpyrrolidine-2-carboxylic acid manufacturer & supplier

Chemical Name:1-propanoylpyrrolidine-2-carboxylic acid

CAS.NO:59785-64-7

Synonyms:1-propionyl-pyrrolidine-2-carboxylic acid;1-Propionylproline;DL-Propionyl-prolin;N-propionylproline;1-propanoylproline

Molecular Formula:C₈H₁₃NO₃

Molecular Weight:171.19400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:371.3ºC at 760 mmHg

Density:1.224g/cm3

Index of Refraction:1.512

PSA:57.61000

Exact Mass:171.09000

LogP:0.40990

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-propionyl-pyrrolidine-2-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-propanoylproline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-propionyl-pyrrolidine-2-carboxylic acid Use and application,DL-Propionyl-prolin technical grade,usp/ep/jp grade.

Related News: Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 1-propanoylpyrrolidine-2-carboxylic acid manufacturer Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 1-propanoylpyrrolidine-2-carboxylic acid supplier Three more patients have been confirmed infected with coronavirus in South Korea, bringing the country’s total to 15, the South Korean Centers for Disease Control and Prevention (KCDC) announced in a press release. 1-propanoylpyrrolidine-2-carboxylic acid vendor In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. 1-propanoylpyrrolidine-2-carboxylic acid factory Some of Amanpour’s counterparts also offered well-wishes on Monday.